TY - JOUR T1 - Clinical features and outcomes of patients with myositis associated-interstitial lung disease JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2246 VL - 58 IS - suppl 65 SP - PA2246 AU - Theodoros Karampitsakos AU - Ourania Papaioannou AU - Serafeim Chrysikos AU - Matthaios Katsaras AU - Georgios Tsirikos AU - Panagiota Tsiri AU - Eirini Zarkadi AU - Panagiotis Efthymiou AU - Vasilina Sotiropoulou AU - Nikolaos Ntoulias AU - Elli Malakounidou AU - Aggeliki Bellou AU - Vasilios Tzilas AU - Evangelos Bouros AU - Fotios Sampsonas AU - Theofanis Karageorgas AU - Katerina Dimakou AU - Demosthenes Bouros AU - Argyris Tzouvelekis Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2246.abstract N2 - Introduction: Myositis associated interstitial lung disease (ILD) seems to be an under-recognized entity.Aim: To present clinical characteristics, radiographic features and outcomes of patients with myositis associated-ILD.Methods: Patients with myositis associated-ILD between 1/1/2018 and 1/1/2021 were prospectively enrolled in the study.Results: Fifteen patients (n=15) were included in the analysis [females: 8, median age (95% CI): 64.0 (56.3 to 68.7), mean baseline FVC%pred±SD: 80.6±20.5, mean baseline DLCO%pred±SD:68.9±25.4, mean %lymphocytes in bronchoalveolar lavage±SD: 29.4±24.1]. ILD preceded muscular involvement in eight patients (53.3%). Most commonly encountered antibodies were anti-Ro52 (n=8, 53.3%), anti-Jo-1 (n=5, 33.3%), anti-MDA5 (n=4, 26.7%), anti-PL-7(n=3, 20%), anti-PL-12 (n=2, 13.3%), anti-Ku (n=2, 13.3%), anti-OJ (n=2, 13.3%). The predominant radiographic pattern was organizing pneumonia in seven patients (46.7%), fibrotic NSIP in five patients (33.3%), and overlap NSIP/organizing pneumonia in three patients (20%). One-year mortality was 20%.Conclusion: Specific ILD radiographic features may herald underlying inflammatory myopathies. Incorporation of ILD radiological patterns in the diagnostic criteria of inflammatory myopathies may lead to timely therapeutic interventions and positively impact patients’ survival.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2246.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -